Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.306 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Rochester, Minn. This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions. InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments: A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND). After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND A Study To Compare Standard Chemotherapy To Therapy With CPX-351 And/or Gilteritinib To To Treat Newly-diagnosed AML With Or Without FLT3 Mutations Rochester, Minn. The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Personalized Neoantigen Peptide-Based Vaccine In Combination With Pembrolizumab For The Treatment Of Advanced Solid Tumors, The PNeoVCA Study Jacksonville, Fla. The purpose of this study is to determine the safety and tolerability of personalized neoantigen peptide administered in combination with pembrolizumab to patients with advanced solid tumors. Patients' tumors will be sequenced during a pre-registration component or will have had successful sequencing pre-study. A personalized neoantigen peptide vaccine containing up to 20 unique peptides will be manufactured for each qualifying patient based on the results. 3D Ultrasound For The Imaging Of Axillary Lymph Nodes In Patients With Breast Cancer Rochester, Minn. The overall goal of this project is to study a new 3D ultrasound imaging technology for evaluation of axillary lymph nodes in patients with breast cancer. A Study To Evaluate Individualized Prehabilitation For People Undergoing Neo-Adjuvant Radiotherapy And Lower Limb Soft-Tissue Sarcoma Surgery Scottsdale/Phoenix, Ariz. The primary objectives of this study are to determine if a tailored prehabilitation program focusing on functional optimization of spared limb tissue in two groups of patients with localized, lower extremity soft tissue sarcoma, one with prehabilitation and one with equal attention and informational support, improves functional outcome as measure by the Toronto Extremity Salvage Score (TESS), to identify the measures and metrics most responsive to the intervention using the (TESS), Six Minute Walk Test (6MWT)[5], wearable Heel2Toe sensor technology and daily step count, and to estimate recruitment, retention, adherence, and acceptability rates. Breath Condensate Of Lung Cancer Patients And Healthy Controls To Measure RNA Species In Exhaled Breath Condensate Rochester, Minn. The purpose of this study is to develop tests for early detection of lung cancer or lung fibrosis based on multiomics analyses of patients’ breath condensates. A Study To Validate DNA Methylation Markers For Universal And Site-specific Guided Cancer Detection Rochester, Minn. The purpose of this study is to validate candidate universal and site-specific methylated DNA markers (MDMs) in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens. First In Human Study Of TORL-1-23 In Participants With Advanced Cancer Rochester, Minn. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer Prospective Use Of Philips ISuite For Interventional Procedures Rochester, Minn. This research study is being done to look at new MRI imaging guidance software, Philips Interventional iSuite software, to see if using will improve the physician's ability to quickly place and guide needle tip position for biopsies and ablations. A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas. GEN3017 will be administered via subcutaneous injections. All participants will receive active drug; no one will be given placebo. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 1212 Ir a página 1313 Ir a página 1414 Ir a página 1515 Ir a página 1616 SiguientePróxima página Profesionales médicos Cancer clinical-trials